This prospective study shows that the rate of azole-resistant Aspergillus fumigatus (ARAF) in an immunocompromised Indian patient population with invasive aspergillosis (IA) is low, 6/706 (0.8%). This low rate supports the continued use of voriconazole as the first line of treatment. However, the ARAF isolates from India in this study exhibited three kinds of unreported cyp51A mutations, of which two were at hot spots, G54R and P216L, while one was at codon Y431C.
Keywords: India; antifungal susceptibility testing; azole-resistant Aspergillus fumigatus; cyp51A mutations; immunocompromised hosts; invasive aspergillosis; risk factor.
Copyright © 2018 American Society for Microbiology.